Kim's Eye Hospital
10
1
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
60%
6 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization
Role: lead
Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy
Role: lead
Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment
Role: lead
Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV
Role: lead
Treat-and-extend Using Aflibercept for Type 3 Neovascularization
Role: lead
Eyes That Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the Real-World Patient Population and Reasons for Exclusion
Role: lead
Intravitreal Aflibercept for Submacular Hemorrhage
Role: lead
Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients
Role: lead
Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy
Role: collaborator
The High Cup/Disc Ratio in Children
Role: lead
All 10 trials loaded